跳至主要内容
临床试验/NCT02875236
NCT02875236终止4 期

Efficacy and Safety of OctaplasLG Administration vs. Crystalloids (Standard) in Patients With Septic Shock - a Randomized, Controlled, Open-label Investigator-initiated Pilot Trial

Rigshospitalet, Denmark1 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2016年9月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
终止
入组人数
5
试验地点
1
主要终点
Microvascular perfusion

研究概览

简要总结

Efficacy and safety of octaplasLG® administration vs. crystalloids (standard) in patients with septic shock - a randomized, controlled, open-label investigator-initiated pilot trial.

详细描述

Recently a great interest in the role of the endothelium in the pathophysiology of sepsis has been introduced. The endothelium is coated by a "thick" endothelial glycocalyx protecting it from becoming activated and prevents capillary leakage. The glycocalyx binds approximately 1-1.5 litres of the plasma portion of the circulating blood and regulates the dynamic exchange between the intra -and extravascular space, therefore, functioning both as a barrier and as a mechano transducer. Damage to the glycocalyx is caused by major trauma, major surgery, or ischemia and reperfusion injury, and resulting in vascular leakage. Damage to the endothelium is further augmented by resuscitation of crystalloids and colloids as well as related to bleeding. Thawed fresh frozen plasma may cause a further "inflammatory hit" towards the glycocalyx and endothelium. The degradation of the glycocalyx increases endothelial permeability with edema formation entitled 'the endothelial leakage syndrome', and resulting in the development of hypotension, pulmonary complications, abdominal compartment syndrome, multi-organ failure and death.

The current strategy for maintaining the intravascular volume in patients with acute critical illness focuses on the administration of crystalloids, such as Ringer-Acetate, and natural colloids. Crystalloids, especially, are known to extravasate and cause edema, which is associated with hypoperfusion and compromised vital organ function by the increased tissue pressure that limits oxygen delivery, and ultimately leading to the complications described above. Until recently, synthetic colloids were the preferred choice of fluids for these patients, but a Scandinavian study in patients with severe sepsis and septic shock (6S trial) demonstrated an increased mortality in patients receiving synthetic colloids, thereby, establishing the adverse effect of such a strategy. Consequently, new resuscitation fluids are needed, preferably not only to support the intravascular volume, but also to support and restore the endothelial integrity.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Factorial
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult intensive care patients AND
  • Septic shock requiring infusion of vasopressor/inotropic agents to maintain blood pressure as defined in international guidelines AND
  • Consent obtainable from patient or by proxy (independent physicians and/or next of kin)

排除标准

  • Documented refusal of blood transfusion OR
  • Treatment with GPIIb/IIIa inhibitors < 24h from screening OR
  • Withdrawal from active therapy OR
  • Previously within 30 days included in a randomised trial, if known at the time of enrolment OR
  • Known Immunoglobulin A deficiency with documented antibodies against Immunoglobulin A OR
  • Known hypersensitivity to OctaplasLG: the active substance, any of the excipients (Sodium citrate dihydrate, Sodium dihydrogenphosphate dihydrate or Glycine) or residues from the manufacturing process (Tri (N-Butyl) Phosphate (TNBP) and Octoxynol (Triton X-100)) OR
  • Known severe deficiencies of protein S OR
  • Pregnancy (non-pregnancy confirmed by patient being postmenopausal or having a negative urine-hCG) OR
  • Severe cirrhotic hepatic failure with expected need for treatment with terlipressin

研究组 & 干预措施

Control

Placebo Comparator

Ringer-acetat

干预措施: OctaplasLG® (Drug)

Intervention

Active Comparator

OctaplasLG®

干预措施: Ringer-acetat (Drug)

结局指标

主要结局

Microvascular perfusion

时间窗: 6 hours after inclusion

Change in microvascular perfusion as evaluated by sidestream darkfield (SDF; MicroVision Medical, Amsterdam, The Netherlands) imaging technique.

Endothelial activation and damage

时间窗: 6 hours after inclusion

Change in biomarkers indicative of endothelial activation and damage (soluble E-selectin, syndecan-1, thrombomodulin, soluble VE-cadherin, nucleosomes)

次要结局

  • Bleeding(1 week)
  • TRALI(30 days)
  • Mortality(From 6 hours until 90 days)
  • Ventilator(through study completion, an average of 1 month)
  • Length of stay in Intensive Care Unit(through study completion, an average of 1 month)
  • Vasopressors(through study completion, an average of 1 month)
  • SAR(30 days)
  • TACO(30 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Thomas Bech Jørgensen

Consultant, Department of Anesthesia and Intensive Care, Bispebjerg Hospital, Principal Investigator.

Rigshospitalet, Denmark

研究点 (1)

Loading locations...

相似试验